<- Go Home
Journey Medical Corporation
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Market Cap
$177.0M
Volume
196.4K
Cash and Equivalents
$25.6M
EBITDA
$1.4M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$44.6M
Profit Margin
65.45%
52 Week High
$9.55
52 Week Low
$4.31
Dividend
N/A
Price / Book Value
N/A
Price / Earnings
-28.15
Price / Tangible Book Value
N/A
Enterprise Value
$176.9M
Enterprise Value / EBITDA
119.72
Operating Income
-$3.0M
Return on Equity
23.77%
Return on Assets
-2.09
Cash and Short Term Investments
$25.6M
Debt
$25.5M
Equity
$32.1M
Revenue
$68.2M
Unlevered FCF
N/A
Sector
Pharmaceuticals
Category
N/A